UMN Pharma Inc. announced consolidated earnings results for the six months ended June 30, 2016. For the period, the company's net sales were JPY 56 million compared with JPY 45 million a year ago. Operating loss was JPY 1,754 million compared with JPY 2,157 million a year ago. Ordinary loss was JPY 1,861 million compared with JPY 2,186 million a year ago. Profit attributable to owners of parent was JPY 1,611 million or JPY 167.62 per basic share compared with JPY 2,183 million or JPY 228.17 per basic share a year ago. Loss before income taxes and minority interests was JPY 1,861.779 million compared with JPY 2,186.674 million a year ago. Net cash used in operating activities was JPY 888.631 million compared with JPY 1,700.323 million a year ago. Purchase of property, plant and equipment was JPY 1,809.477 million compared with JPY 14.668 million a year ago.

For the year ending December 31, 2016, the company forecasts net sales in the range of JPY 2,428 million to JPY 2,044 million, operating loss in the range of JPY 2,315 million to JPY 2,282 million, ordinary loss in the range of JPY 2,608 million to JPY 2,575 million and net loss attributable to owners of parent in the range of JPY 2,366 million to JPY 2,332 million or JPY 246.68 to JPY 243.22 per share.